University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Mark Moasser, M.D.

Breast cancer specialist

Dr. Mark Moasser is a medical oncologist specializing in breast cancer treatment and research. In the laboratory, he works to develop more effective therapies for the treatment of breast cancer and designs clinical trials that he brings to the clinic. He has published his work in numerous scientific journals and regularly presents his findings at scientific meetings.

Moasser graduated from Tufts University School of Medicine and completed his residency and fellowship training at The New York Hospital -- Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York.

Clinics

Carol Franc Buck Breast Care Center
1600 Divisadero St., Second Floor
San Francisco, CA 94115
Phone: (415) 353-7070
Surgery Fax: (415) 353-7050
Oncology Fax: (415) 353-7692

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Mark Moasser

Education

Tufts University School of Medicine 1988

Residencies

New York Hospital/Cornell Medical Center, Internal Medicine 1991

Fellowships

Memorial Sloan-Kettering Cancer Center, Medical Oncology 1995
Memorial Sloan-Kettering Cancer Center, Breast Cancer 1996

Selected Research and Publications

  1. Moasser MM. Two Dimensions in Targeting HER2. J Clin Oncol. 2014 Jul 1; 32(19):2074-7.
  2. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9.
  3. Littlefield P, Moasser MM, Jura N. An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase. Chem Biol. 2014 Apr 24; 21(4):453-8.
  4. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013 Feb 1; 73(3):1168-79.
  5. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012 Nov 1; 447(3):417-25.
  6. Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene. 2012 Jan 26; 31(4):419-31.
  7. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 7; 104(12):1828-35.
  8. Spassov DS, Ahuja D, Wong CH, Moasser MM. The structural features of Trask that mediate its anti-adhesive functions. PLoS One. 2011; 6(4):e19154.
  9. Spassov DS, Wong CH, Moasser MM. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle. 2011 Apr 15; 10(8):1225-32.
  10. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407.
  11. Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011 Feb; 31(4):766-82.
  12. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010 Dec; 21(9):944-50.
  13. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010 Mar 1; 16(5):1373-83.
  14. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27; 2(16):16ra7.
  15. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75.
  16. Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009 May; 29(5):1071-9.
  17. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009 May; 174(5):1756-65.
  18. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009 Apr 1; 15(7):2311-22.
  19. Arkin M, Moasser MM. HER-2-directed, small-molecule antagonists. Curr Opin Investig Drugs. 2008 Dec; 9(12):1264-76.
  20. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7878-83.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.